AffiliationCancer Inflammation and Immunity Group, CRUK Manchester Institute, The University of Manchester, Manchester, England, UK
MetadataShow full item record
AbstractIn this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, counteract this effect, representing an attractive target for therapeutic intervention.
CitationResolving the dark side of therapy-driven cancer cell death. 2018, 215(1): 9-11 J Exp Med
JournalThe Journal of Experimental Medicine